CompuMed Previews CompuBRIDGE Solution for Electronic Medical Records
CompuMed, Inc. (OTCBB:CMPD) — a medical informatics company serving the healthcare community with diagnostic software solutions — today announced that it will preview its new CompuBRIDGE(TM) telecardiology electronic medical records (EMR) solution at the National Conference on Correctional Health Care (NCCHC), taking place through Wednesday in Chicago.
The CompuBRIDGE EMR is designed to capture and integrate electrocardiogram (ECG) results and over-reads into an existing EMR system. Integration does not require the practice to employ additional software, hardware or specialized servers. For facilities without a general EMR system, CompuMed offers hosted solutions that provide access to ECG data via any Internet enabled computer. CompuMed expects to release its CompuBRIDGE EMR system after testing with beta customers.
“CompuBRIDGE EMR is part of our strategy to help healthcare providers implement an integrated digital information solution,” said CompuMed CEO Maurizio Vecchione. “We use a standards based architecture for ease of integration and optimal interoperability. It allows our clients to automatically integrate ECGs and over-reads with most EMR systems.”
CompuBRIDGE EMR will provide users of CompuMed’s telecardiology services with the ability to data mine patient records and electronically transfer those records to their own EMR systems, such as patient administrative systems, electronic practice management, laboratory information systems, dietary and pharmacy.
Development of the CompuBRIDGE EMR benefited from CompuMed’s experience as one of the leading providers of remote ECG services for the correctional facility market. Over the past decade, the company’s flagship CardioGram system has become the telecardiology solution of choice for a significant number of the state correctional prison systems across the US.
“Nowhere is the challenge of providing quality healthcare more complex than in a correctional facility,” added Vecchione. “Electronic medical records have been shown to have an impact on the safety, effectiveness and cost of healthcare by having the right information at the right place at the right time. CompuBRIDGE, built with the experience of our correctional industry success, can help correctional healthcare customers as well as any other healthcare providers who use ECGs extensively transition into integrated digital medical records.”
About CompuMed:
CompuMed, Inc. (OTCBB:CMPD) develops and markets products and services that combine advanced imaging with medical informatics. Its focus is on analysis and remote monitoring for patients with cardiovascular and musculoskeletal diseases. The Company has specialized expertise and intellectual property in telemonitoring imaging and analysis designed to improve healthcare provider workflow and patient care while reducing costs. CompuMed’s core products, the OsteoGram(R) and CardioGram(TM), are cleared by the FDA and reimbursable by Medicare. The OsteoGram is a non-invasive diagnostic system that has been proven by many clinical studies to provide effective and accurate bone density measurement for screening osteoporosis and assessing hip fracture risk. The OsteoGram has significant cost advantages over other technologies in the marketplace. The CardioGram system is one of the first telecommunication networks designed to remotely interpret electrocardiograms and is used by private practice, as well as government and corporate healthcare providers nationwide. The CardioGram delivers online electrocardiogram interpretations within minutes of receipt and has the additional capability of automatically providing an over-read (i.e., follow-up review) by a cardiologist. CompuMed is headquartered in Los Angeles and distributes its products worldwide both directly and through OEM partners. Visit CompuMed on-line at www.compumed.net.
Statements contained in this press release that are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth, results of contracts and other financial results, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Company’s plans, objectives, expectations and intentions are based largely on management’s expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-KSB and Quarterly Reports on Form 10-QSB. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.